The end of
bacterial
resistance.
One engine, three fronts
A single patented composition of methylglyoxal, advanced across antibacterial, antiviral, and angiogenic pathways.
Three therapeutic fronts
One engine.
Three fronts.
The same patented composition is deployed against three distinct clinical problems, each grounded in the same multi-site disruptive mechanism.
-
Antibacterial
The end of bacterial resistance.
Patented methylglyoxal disrupts the bacterial cell wall through a multi-site mechanism pathogens cannot route around. No evolutionary resistance has been observed across two decades.
-
Antiviral
An effective antiviral.
The same composition acts against enveloped respiratory viruses at the point of entry.
-
Angiogenic
An effective angiogenic.
Promotes angiogenesis and accelerates tissue repair through the wound-healing and regenerative pathway.
By the evidence
A platform built
on durability.
Two decades of independent study, two patented assets, three expedited regulatory pathways, and a target list defined by the World Health Organization.
20+ yrs
No observed evolutionary resistance
2
Parallel patented assets, botanical and synthetic
3
Expedited FDA pathways in play
WHO list
Multi-drug-resistant target pathogens
The platform
Not one molecule.
A patented platform.
Two independently patented compositions advance the same engine along two parallel regulatory routes, multiplying delivery options and de-risking capital.
Botanical matrix
Lepto242
- Composition
- Patented Medical Grade Manuka composition.
- Human use
- Documented human use since 1996.
- Regulatory route
- 505(b)1 botanical FDA pathway.
Synthetic small molecule
Lgx242
- Composition
- Synthetic methylglyoxal derivative engineered for precision delivery.
- Designations
- Qualifies QIDP under the GAIN Act: +5 years exclusivity and Fast Track.
- Regulatory route
- LPAD pathway for limited, highly resistant populations.
Our mission
To usher in the Post-Resistance Era by delivering safe, structurally disruptive antimicrobials to millions of patients globally.
Contact